硬皮症治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

2023年，全球硬皮症治療市場估值為22億美元，預計2024年至2032年複合年成長率為6.8%。 。全球系統性和局部硬皮症發病率的上升正在推動對有效治療的需求。國家硬皮病基金會報告稱，大約 30 萬美國人患有硬皮病，其中許多病例可能未被診斷出來。認知的提高和早期診斷進一步推動了對專業治療的需求。研究和開發方面的大量投資正在為市場成長創造機會。

整個硬皮症治療產業根據藥物類別、適應症、給藥途徑和地區進行分類。

市場依藥物類別分為磷酸二酯酶前列環素類似物、5抑制劑（PHA）、免疫抑制劑、內皮素受體拮抗劑、鈣通道阻斷劑、止痛藥等。 2023年，免疫抑制劑領域的收入最高，為7.816億美元。免疫抑制劑因其在治療系統性硬皮症方面的作用而在市場上佔據主導地位。這些藥物透過抑制過度活躍的免疫反應來減少發炎和纖維化。它們在控制肺纖維化和腎臟受累等嚴重症狀方面的有效性使其在治療中至關重要。

根據跡象，市場分為系統性硬皮症和局部硬皮症。系統性硬皮症細分市場在 2023 年的收入為 19 億美元。它影響內臟器官並涉及廣泛的纖維化，導致顯著的發病率和死亡率。這推動了對全面和積極治療策略的需求。人們越來越認知到系統性硬皮症對生活品質的影響，這刺激了對專門治療方法的需求。此疾病需要採取多方面的方法來解決肺纖維化、胃腸道問題和腎臟受累等症狀和併發症。

2023年，北美硬皮症治療市場產生了11億美元的收入，預計2024年至2032年複合年成長率為5.3%。正在上升專業人士和患者。該地區先進的醫療基礎設施有利於早期診斷和管理，從而刺激了需求。北美強力的監管框架和孤兒藥支持政策鼓勵硬皮病治療方法的開發和批准。加上大量的研發資金，加速了創新療法進入市場的速度。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 硬皮症盛行率增加
    • 患者意識不斷提高
    • 政府的便利支持與舉措
  • 產業陷阱與挑戰
    • 不良反應和安全問題
• 成長潛力分析
• 監管環境
• 管道分析
• 技術景觀
• 波特的分析
• PESTEL分析
• 未來市場趨勢
• 差距分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按藥物類別，2021 - 2032 年

• 主要趨勢
• 免疫抑制劑
• 磷酸二酯酶 5 抑制劑 - PHA
• 內皮素受體拮抗劑
• 前列環素類似物
• 鈣通道阻斷劑
• 止痛藥
• 其他藥物類別

第 6 章：市場估計與預測：按指標分類，2021 - 2032 年

• 主要趨勢
• 系統性硬皮症
• 局限性硬皮症

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

• 主要趨勢
• 口服
• 可注射
• 其他給藥途徑

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• Actelion (Johnson and Johnson)
• Akashi Therapeutics
• Astellas Pharma
• Bayer AG
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Galderma Laboratories
• Genkyotex
• Gilead Sciences
• GSK plc
• Pfizer, Inc.
• Prometic Life Sciences, Inc.
• F. Hoffmann La Roche Ltd.
• Sanofi SA
• United Therapeutics

The Global Scleroderma Therapeutics Market was valued at USD 2.2 billion in 2023 and is projected to grow at a CAGR of 6.8% from 2024 to 2032. This growth is driven by the increasing prevalence of scleroderma and rising patient awareness. The rising incidence of both systemic and localized scleroderma globally is boosting demand for effective treatments. The National Scleroderma Foundation reports that approximately 300,000 Americans are affected by scleroderma, with many cases likely undiagnosed. Increased awareness and earlier diagnosis are further driving demand for specialized treatments. Significant investments in research and development are creating opportunities for market growth.

The overall scleroderma therapeutics industry is classified based on the drug class, indication, route of administration, and region.

The market is segmented by drug class into phosphodiesterase prostacyclin analogs, 5 inhibitors (PHA), immunosuppressors, endothelin receptor antagonists, calcium channel blockers, analgesics, and others. In 2023, the immunosuppressors segment generated the highest revenue of USD 781.6 million. Immunosuppressors dominate the market due to their role in managing systemic scleroderma. These drugs reduce inflammation and fibrosis by suppressing the overactive immune response. Their effectiveness in controlling severe manifestations like lung fibrosis and renal involvement makes them essential in treatment.

By indication, the market is divided into systemic and localized scleroderma. The systemic scleroderma segment led with a revenue of USD 1.9 billion in 2023. Systemic scleroderma holds a larger market share due to its severity and complexity. It affects internal organs and involves widespread fibrosis, leading to significant morbidity and mortality. This drives demand for comprehensive and aggressive treatment strategies. The increasing recognition of systemic scleroderma's impact on quality-of-life fuels the demand for specialized therapeutics. The disease requires a multifaceted approach to address symptoms and complications like pulmonary fibrosis, gastrointestinal issues, and renal involvement.

In 2023, the North American scleroderma therapeutics market generated USD 1.1 billion in revenue and is expected to grow at a CAGR of 5.3% from 2024 to 2032. Demand in North America is rising due to the increasing prevalence of the disease and heightened awareness among healthcare professionals and patients. The region's advanced healthcare infrastructure facilitates early diagnosis and management, boosting demand. North America's strong regulatory framework and supportive policies for orphan drugs encourage the development and approval of scleroderma treatments. Combined with substantial R&D funding, this accelerates the introduction of innovative therapies into the market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of scleroderma
    • 3.2.1.2 Rising patient awareness
    • 3.2.1.3 Facilitative government support and initiatives
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Adverse effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Technology landscape
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Future market trends
• 3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Immunosuppressors
• 5.3 Phosphodiesterase 5 inhibitors - PHA
• 5.4 Endothelin receptor antagonists
• 5.5 Prostacyclin analogues
• 5.6 Calcium channel blockers
• 5.7 Analgesics
• 5.8 Other drug classes

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Systemic scleroderma
• 6.3 Localized scleroderma

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable
• 7.4 Other routes of administrations

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Actelion (Johnson and Johnson)
• 9.2 Akashi Therapeutics
• 9.3 Astellas Pharma
• 9.4 Bayer AG
• 9.5 Boehringer Ingelheim
• 9.6 Bristol-Myers Squibb
• 9.7 Galderma Laboratories
• 9.8 Genkyotex
• 9.9 Gilead Sciences
• 9.10 GSK plc
• 9.11 Pfizer, Inc.
• 9.12 Prometic Life Sciences, Inc.
• 9.13 F. Hoffmann La Roche Ltd.
• 9.14 Sanofi SA
• 9.15 United Therapeutics